GLYPHARMA THERAPEUTIC

GLyPharma was created in Montréal in August 2012 for the purpose of a strategic partnership between Ferring Pharmaceuticals, a European pharmaceutical company specialized in the discovery and development of active peptides, FONDS de solidarité FTQ and CTI Life Sciences Fund. The compound, FE 203799, is a long-acting GLP-2 receptor agonist, with intestine-trophic and intestine-protective activity. GLyPharma is granted by Ferring an exclusive worldwide license for development and commercialization of this compound as first-in-class indication in supportive care in oncology for protecting from chemotherapy-induced intestinal mucositis.